Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Avadel Pharmaceuticals (AVDL – Research ...

Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a ...

Ascentage Pharma (6855.HK) is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in ...

Ascentage Pharma (6855.HK) is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in ...

Enyo Pharma is a biopharmaceutical company that develops innovative ... non-bile acid NR1H4 agonist that treats alport syndrome; EYP651 targets chronic kidney disease and nonalcoholic steatohepatitis; ...

BAY-3283142 is under clinical development by Bayer and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure ... data points from various databases found on GlobalData’s ...

Yunnan Baiyao Group Co. Ltd. A 0.55% ¥107B Tasly Pharmaceutical Group Co. Ltd. A 1.09% ¥21.97B Jiangsu Hengrui Medicine Co. Ltd. A-0.62% ¥293.66B Zhejiang Hisun Pharmaceutical Co. Ltd. A 0.36% ...

Sanofi and Regeneron are in the process of testing out blockbuster biologic Dupixent in the indication, for one, and clinical-stage biotechs Asana BioSciences and Afecta Pharmaceuticals are both ...

Dec 19 (Reuters) - The U.S. Food and Drug Administration has declined to approve Zealand Pharma's (ZELA.CO), opens new tab bowel disease drug and sought an additional trial to confirm the drug's ...